<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010334</article-id><article-id pub-id-type="publisher-id">ACM-37993</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_10818127.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  超声引导下经皮穿刺射频消融术治疗尿毒症难治性继发性甲状旁腺功能亢进的临床疗效分析
  The Clinical Efficacy Analysis of Ultrasound Guided Percutaneous Radiofrequency Ablation in the Treatment of Uremic Refractory Secondary Hyperparathyroidism
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>宝福</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>覃</surname><given-names>夏川</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>昌伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>波良</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谢</surname><given-names>席胜</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南充市中心医院(川北医学院第二临床学院)肾内科，四川 南充</addr-line></aff><aff id="aff3"><addr-line>南充市中心医院(川北医学院第二临床学院)超声科，四川 南充</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2209</fpage><lpage>2215</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨超声引导下经皮穿刺射频消融术治疗尿毒症难治性继发性甲状旁腺功能亢进的临床疗效。方法：选取30例尿毒症继发甲状旁腺功能亢进患者，于高频超声引导下行经皮穿刺射频消融治疗，观察患者治疗前后血清甲状旁腺激素、血清钙及血清磷等指标变化，评价临床疗效及术后不良反应。结果：共消融增生甲状旁腺118枚。与治疗前比较，治疗后1 d、3 d、1 w、1 m、3 m、6 m及10 m的血清甲状旁腺激素及血清磷水平明显降低，差异均有统计学意义(P &lt; 0.05)。术后骨痛、皮肤瘙痒等临床症状明显缓解。手术成功率100%，术后并发症主要为声音嘶哑、低钙抽搐，但可恢复正常。术后用药明显减少，以补钙药物为主。结论：射频消融术治疗尿毒症难治性继发甲状旁腺功能亢进的疗效肯定，可有效降低血清甲状旁腺激素水平，缓解症状，且创伤较小，不良反应少，值得临床推广应用。
    Objective: To explore the clinical effect of ultrasound-guided percutaneous radiofrequency ablation in the treatment of uremic refractory secondary hyperparathyroidism. Methods: 30 patients with uremia secondary hyperparathyroidism were selected and treated by percutaneous radiofrequency ablation under the guidance of high frequency ultrasound. The changes of serum parathyroid hormone, serum calcium and serum phosphorus were observed before and after treatment to evaluate the clinical effect and adverse reactions. Results: 118 hyperparathyroids were ablated. Compared with that before treatment, the levels of parathyroid hormone and serum phosphorus were significantly lower on the 1 d, 3 d, 1 w, 1 m, 3 m, 6 m and 10 m after treatment (P &lt; 0.05). The clinical symptoms such as osteodynia and pruritus were relieved obviously. The success rate of the operation was 100%. The main postoperative complications were hoarseness, hypocalcemia convulsion, but it could return to normal. Postoperative medication was significantly reduced, mainly calcium supplements. Conclusion: Radiofrequency ablation is effective in the treatment of refractory secondary hyperparathyroidism of uremia. It can effectively reduce the level of serum parathyroid hormone, relieve symptoms, and has less trauma and less adverse reactions. It is worthy of clinical application. 
  
 
</p></abstract><kwd-group><kwd>继发性甲状旁腺功能亢进症，尿毒症，射频消融术, Secondary Hyperparathyroidism</kwd><kwd> Uremia</kwd><kwd> Radiofrequency Ablation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨超声引导下经皮穿刺射频消融术治疗尿毒症难治性继发性甲状旁腺功能亢进的临床疗效。方法：选取30例尿毒症继发甲状旁腺功能亢进患者，于高频超声引导下行经皮穿刺射频消融治疗，观察患者治疗前后血清甲状旁腺激素、血清钙及血清磷等指标变化，评价临床疗效及术后不良反应。结果：共消融增生甲状旁腺118枚。与治疗前比较，治疗后1 d、3 d、1 w、1 m、3 m、6 m及10 m的血清甲状旁腺激素及血清磷水平明显降低，差异均有统计学意义(P &lt; 0.05)。术后骨痛、皮肤瘙痒等临床症状明显缓解。手术成功率100%，术后并发症主要为声音嘶哑、低钙抽搐，但可恢复正常。术后用药明显减少，以补钙药物为主。结论：射频消融术治疗尿毒症难治性继发甲状旁腺功能亢进的疗效肯定，可有效降低血清甲状旁腺激素水平，缓解症状，且创伤较小，不良反应少，值得临床推广应用。</p></sec><sec id="s2"><title>关键词</title><p>继发性甲状旁腺功能亢进症，尿毒症，射频消融术</p></sec><sec id="s3"><title>The Clinical Efficacy Analysis of Ultrasound Guided Percutaneous Radiofrequency Ablation in the Treatment of Uremic Refractory Secondary Hyperparathyroidism<sup> </sup></title><p>Baofu Wang<sup>1*</sup>, Xiachuan Qin<sup>2</sup>, Changwei Lin<sup>1</sup>, Boliang Li<sup>1</sup>, Xisheng Xie<sup>1</sup></p><p><sup>1</sup>Department of Nephrology, Nanchong Central Hospital (Second Clinical College of North Sichuan Medical College), Nanchong Sichuan</p><p><sup>2</sup>Department of Ultrasound, Nanchong Central Hospital (Second Clinical College of North Sichuan Medical College), Nanchong Sichuan</p><p><img src="//html.hanspub.org/file/1-1571545x5_hanspub.png" /></p><p>Received: Sep. 18<sup>th</sup>, 2020; accepted: Oct. 3<sup>rd</sup>, 2020; published: Oct. 10<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/1-1571545x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the clinical effect of ultrasound-guided percutaneous radiofrequency ablation in the treatment of uremic refractory secondary hyperparathyroidism. Methods: 30 patients with uremia secondary hyperparathyroidism were selected and treated by percutaneous radiofrequency ablation under the guidance of high frequency ultrasound. The changes of serum parathyroid hormone, serum calcium and serum phosphorus were observed before and after treatment to evaluate the clinical effect and adverse reactions. Results: 118 hyperparathyroids were ablated. Compared with that before treatment, the levels of parathyroid hormone and serum phosphorus were significantly lower on the 1 d, 3 d, 1 w, 1 m, 3 m, 6 m and 10 m after treatment (P &lt; 0.05). The clinical symptoms such as osteodynia and pruritus were relieved obviously. The success rate of the operation was 100%. The main postoperative complications were hoarseness, hypocalcemia convulsion, but it could return to normal. Postoperative medication was significantly reduced, mainly calcium supplements. Conclusion: Radiofrequency ablation is effective in the treatment of refractory secondary hyperparathyroidism of uremia. It can effectively reduce the level of serum parathyroid hormone, relieve symptoms, and has less trauma and less adverse reactions. It is worthy of clinical application.</p><p>Keywords:Secondary Hyperparathyroidism, Uremia, Radiofrequency Ablation</p><disp-formula id="hanspub.37993-formula2"><graphic xlink:href="//html.hanspub.org/file/1-1571545x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1571545x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-1571545x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>继发甲状旁腺功能亢进(secondary hyperparathyroidism, SHPT)是慢性肾脏病(Chronic Kidney Disease, CKD)患者常见的严重并发症之一 [<xref ref-type="bibr" rid="hanspub.37993-ref1">1</xref>]。SHPT不仅是CKD患者的并发症，而且也是CKD患者心脑血管事件和死亡的独立危险因素，严重影响CKD患者的生存率和生存质量及预后 [<xref ref-type="bibr" rid="hanspub.37993-ref2">2</xref>]。SHPT在维持性血液透析尿毒症患者中发病率可高达50%以上，呈现发病率高，控制达标率低的趋势，严重影响着透析病人的生活和生存质量 [<xref ref-type="bibr" rid="hanspub.37993-ref3">3</xref>]。目前，SHPT的治疗方法主要包括药物、腺体切除手术和超声引导下热消融微创术。对于药物难治性SHPT，外科切除是指南推荐的主要方式 [<xref ref-type="bibr" rid="hanspub.37993-ref4">4</xref>]，但有部分患者因为严重心肺功能不全等原因，不能耐受或不愿进行全身麻醉下外科手术治疗。射频消融技术是治疗难治性SHPT的另一治疗手段，具有微创、痛苦小、可反复施行、疗效确切等优点。现将我院30例尿毒症SHPT患者行甲状旁腺射频消融结果及疗效分析报道如下。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选取2018年9月至2020年01月南充市中心医院收治的30例尿毒症伴难治性SHPT患者为观察对象。纳入标准 [<xref ref-type="bibr" rid="hanspub.37993-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.37993-ref6">6</xref>] 1) 年龄18~75岁，规律性每周三次血液透析；2) 严重SHPT，iPTH持续 &gt; 800 pg/ml；3) 具备至少一枚甲状旁腺增大的影像学证据，如高频彩色超声显示甲状旁腺增大，直径 &gt; 1 cm并且有丰富的血流 [<xref ref-type="bibr" rid="hanspub.37993-ref7">7</xref>]。排除标准：1) 原发性甲状旁腺功能亢进；2) 99mTc-MIBI双时相显像发现颈部以外存在异位甲状旁腺者；3) 精神障碍无法配合操作患者；4) 术前候镜检查有异常且影响发声的患者；5) 无法完成随访的患者。所有患者均知情同意，签署消融治疗同意书，研究方案获医院医学伦理委员会批准。</p></sec><sec id="s6_2"><title>2.2. 术前准备及方法</title><sec id="s6_2_1"><title>2.2.1. 术前准备</title><p>所有病人术前需完善血常规、生化、iPTH、凝血、心电图、胸部X片、超声心动图、甲状旁腺彩超、99mTc-MIBI双时相显像及候镜检查。术前1天行无肝素血液透析1次。</p></sec><sec id="s6_2_2"><title>2.2.2. 仪器设备与方法</title><p>1) 射频消融系统：使用绵阳立德公司生产的射频消融系统，射频治疗仪主机型号 RF-120S，射频输出功率最大为200 W，频率为480 KHz，温度监控：5℃~95℃，阻抗监控：10~800 omhs，冷却泵：VP01。所选射频针的型号：立德公司生产一次性单极射频消融电极针，电极针18-07s07F。</p><p>2) 彩色超声诊断仪：采用荷兰Philips公司生产的7C彩超诊断仪，配备高频线阵探头，频率12 Hz。</p><p>3) 超声造影剂：使用意大利Bracco公司研制的造影剂，注射用六氟化硫微泡(SonoVue)，剂量4.8 mg/5 ml，使用前向瓶内推5 ml生理盐水，充分摇匀后，于RFA术前及术后经静脉迅速推注1.2 ml混悬液，后再快速推注5 ml生理盐水。</p><p>4) 射频消融方法：在消融前行超声检查及造影明确甲状旁腺位置、大小，数目，并设计安全消融路径。患者取仰卧位，将软枕置于其颈后以充分暴露手术部位，常规皮肤消毒铺巾，2%利多卡因局部浸润麻醉穿刺处皮肤。将0.9%氯化钠注射液在超声引导下注射至甲状旁腺周围，建立隔离带，与周围组织间距5 mm使腺体与周围组织分离以保护颈动脉及喉返神经，防止消融过程热损伤。在超声引导下将消融针置入甲状旁腺内开始消融，使用立德射频消融仪，频率设定为200~500 kHz，功率设定为30~35 W，消融从旁腺下方开始逐渐往靠近探头方向行移动消融，使气体覆盖腺体，消融后立即行超声造影，腺体无增强意味着消融完全。消融一侧后，嘱患者说话，观察有无声音改变，无声音改变继续对侧消融。如果出现发音嘶哑或呼吸困难则立即停止消融手术。术中记录每枚甲状旁腺消融的时间及功率。</p></sec><sec id="s6_2_3"><title>2.2.3. 术后处理</title><p>1) 所有患者术后使用心电监护仪监测生命体征，术后给予冰敷手术部位6 h，观察有无抽搐、四肢麻木等低钙表现；有无声音嘶哑，评估有无喉返神经损伤。2) 术后定期检测血清钙、血清磷、血iPTH 情况，根据患者症状及血钙情况调整补钙剂量 [<xref ref-type="bibr" rid="hanspub.37993-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.37993-ref9">9</xref>]。</p></sec></sec></sec><sec id="s7"><title>3. 观察指标和疗效判定</title><p>1) 收集所有患者的术后第1 d、3 d、1 w、1 m、3 m、6 m、10 m (最后随访时间平均为10 m)的血清钙、磷、血清甲状旁腺激素(iPTH)等生化指标，根据改善全球肾脏病预后组织(Kidney Disease Improving Global Outcomes, KDIGO) [<xref ref-type="bibr" rid="hanspub.37993-ref2">2</xref>] 指南建议CKD5期及透析患者iPTH应维持在正常高限的2~9倍(130~600 pg/ml)，血钙2.10~2.37 mmol/L，血磷1.13~1.78 mmol/L (CKD 5期及透析患者)，0.87~1.48 mmol/L (CKD 3~4期)，钙磷乘积 &lt; 55 mg<sup>2</sup>/dl<sup>2</sup> [<xref ref-type="bibr" rid="hanspub.37993-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.37993-ref10">10</xref>]。</p><p>2) 术前、术后临床主观症状骨关节痛、皮肤瘙痒等进行观察。</p><p>3) 手术的成功率以术后iPTH下降率大于术前的50%，手术复发以术后6个月iPTH上升超过300 pg/ml复发，KDOQI指南把甲状旁腺激素(iPTH) &lt; 100 pg/ml作为低转运性骨病的诊断标准之一 [<xref ref-type="bibr" rid="hanspub.37993-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37993-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.37993-ref11">11</xref>]。</p><p>4) 手术时间及术后并发症。</p><p>手术并发症主要统计术后对喉返神经的损害如声音嘶哑、失音、吞咽困难等，以及伤口感染情况和术后出现严重低钙血症导致的四肢抽搐情况。</p><p>5) 对比术前、术后使用补钙、降磷药物及治疗甲状旁腺功能亢进药物的情况。</p><p>统计术前使用补钙药物(碳酸钙D3、葡萄糖酸钙注射液)、降磷药物(醋酸钙、碳酸澜、司维拉姆)及治疗甲状旁腺功能亢进药物(骨化三醇、阿尔法骨化醇、骨化三醇注射液、西钠卡塞)等。</p>统计方法<p>采用SPSS 22.0统计学软件进行统计分析。计量资料以X &#177; s表示，组间比较采用独立样本t检验，计数资料组间比较采用x<sup>2</sup>检验；以P &lt; 0.05为差异有统计学意义。</p></sec><sec id="s8"><title>4. 结果</title><sec id="s8_1"><title>4.1. 基线情况</title><p>30例患者均为血液透析病人，其中男性14例，女性16例，年龄32~74岁，平均年龄45.10 &#177; 12.01 岁；透析龄3~7年，平均透析龄3.9 &#177; 1.6年；随访时间：5~16月，平均随访时间10.8 &#177; 3.6月。通过高频超声和99mTc-MIBI双时相显像核对甲状旁腺数目及大小，甲状旁腺大小平均为15.8 &#177; 2.6 mm；甲状旁腺数目中三个甲状旁腺有4例，五个甲状旁腺有2例，24例患者为四个甲状旁腺。主要临床表现为骨痛和皮肤瘙痒，分别为10例和7例，其中5例既有骨痛又有皮肤瘙痒，其他患者无明显表现，具体见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General informatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >性别比(M/F)</th><th align="center" valign="middle"  rowspan="2"  >年龄(年)</th><th align="center" valign="middle"  rowspan="2"  >透析龄(年)</th><th align="center" valign="middle"  rowspan="2"  >透析频率(次/周)</th><th align="center" valign="middle"  rowspan="2"  >甲状旁腺大小(mm)</th><th align="center" valign="middle"  rowspan="2"  >甲状旁腺数(3/4/5)</th><th align="center" valign="middle"  colspan="2"  >临床症状(例)</th></tr></thead><tr><td align="center" valign="middle" >骨痛</td><td align="center" valign="middle" >皮肤瘙痒</td></tr><tr><td align="center" valign="middle" >14/16</td><td align="center" valign="middle" >45.1 &#177; 12.01</td><td align="center" valign="middle" >3.9 &#177; 1.6</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >15.8 &#177; 2.6</td><td align="center" valign="middle" >4/24/2</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >7</td></tr></tbody></table></table-wrap><p>表1. 一般情况</p></sec><sec id="s8_2"><title>4.2. 血生化指标比较</title><p>所有患者血清iPTH、P 在术后均明显下降，术后与术前相比，P &lt; 0.001，有统计学差异；术后1 d与术后1 w相比，P &lt; 0.05，差异有统计学意义，术后1 w、1 m、3 m、6 m、10 m相比，P &gt; 0.05，无统计学意义，所以术后1 w血iPTH、P趋于稳定，术后随访无明显反弹现象，考虑消融成功。术后血钙有明显下降趋势，经药物治疗后好转，具体见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Changes of iPTH, Ca and P after operatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >iPTH (pg/ml)</th><th align="center" valign="middle" >Ca (mmol/l)</th><th align="center" valign="middle" >P (mmol/l)</th></tr></thead><tr><td align="center" valign="middle" >术前</td><td align="center" valign="middle" >2994.4 &#177; 463</td><td align="center" valign="middle" >2.40 &#177; 0.15</td><td align="center" valign="middle" >1.91 &#177; 0.18</td></tr><tr><td align="center" valign="middle" >术后1 d</td><td align="center" valign="middle" >418.6 &#177; 43★</td><td align="center" valign="middle" >2.27 &#177; 0.1★</td><td align="center" valign="middle" >1.74 &#177; 0.27★</td></tr><tr><td align="center" valign="middle" >术后3 d</td><td align="center" valign="middle" >254.7 &#177; 11★△</td><td align="center" valign="middle" >1.89 &#177; 0.12★△</td><td align="center" valign="middle" >1.48 &#177; 0.15★△</td></tr><tr><td align="center" valign="middle" >术后1 w</td><td align="center" valign="middle" >189.2 &#177; 13★△□</td><td align="center" valign="middle" >2.17 &#177; 0.08★△□</td><td align="center" valign="middle" >1.15 &#177; 0.14★△□</td></tr><tr><td align="center" valign="middle" >术后1 m</td><td align="center" valign="middle" >203.6 &#177; 9★△□</td><td align="center" valign="middle" >2.16 &#177; 0.07★△□</td><td align="center" valign="middle" >1.20 &#177; 0.07★△□</td></tr><tr><td align="center" valign="middle" >术后3 m</td><td align="center" valign="middle" >182.5 &#177; 13★△□</td><td align="center" valign="middle" >2.21 &#177; 0.03★△□</td><td align="center" valign="middle" >1.18 &#177; 0.06★△□</td></tr><tr><td align="center" valign="middle" >术后6 m</td><td align="center" valign="middle" >193.1 &#177; 15★△□</td><td align="center" valign="middle" >2.20 &#177; 0.06★△□</td><td align="center" valign="middle" >1.20 &#177; 0.06★△□</td></tr><tr><td align="center" valign="middle" >术后10 m</td><td align="center" valign="middle" >186.3 &#177; 14★△□</td><td align="center" valign="middle" >2.19 &#177; 0.11★△□</td><td align="center" valign="middle" >1.17 &#177; 0.09★△□</td></tr></tbody></table></table-wrap><p>表2. 术后iPTH、Ca、P变化情况</p><p>注：★与术前比较p &lt; 0.001；△与术后1天比较p &lt; 0.05；□与术后1周比较p &gt; 0.05。</p></sec><sec id="s8_3"><title>4.3. 临床症状改善情况</title><p>30例患者中有10存在不同程度骨痛，7例存在皮肤瘙痒，5例患者同时存在骨痛和皮肤瘙痒。手术后上述患者骨痛和皮肤瘙痒明显好转。3.4手术成功率及手术后并发症</p><p>手术成功率为100%，6个月均无复发。术后并发症常见为声音嘶哑和低钙抽搐，声音嘶哑在6 m内均可逐渐恢复，术后给予补钙后抽搐得到缓解。术后出现低转运骨病6人，在随访过程中未出现明显严重临床表现，具体见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Postoperative complication</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >并发症</th><th align="center" valign="middle" >例数(个)</th><th align="center" valign="middle" >百分率(%)</th></tr></thead><tr><td align="center" valign="middle" >声音嘶哑</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >失声</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >吞咽困难</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >伤口感染</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >严重低钙血症伴抽搐</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.3</td></tr><tr><td align="center" valign="middle" >术后iPTH持续 &lt; 100 pg /ml</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >20.0</td></tr></tbody></table></table-wrap><p>表3. 术后并发症情况</p></sec><sec id="s8_4"><title>4.4. 术前、术后用药比较</title><p>术后iPTH、P明显下降，处于达标范围内，故所有病人停用降磷及抗甲状旁腺功能亢进药物，因存在低钙血症，需要口服补钙治疗，具体见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Drug use before and after operatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >用药</th><th align="center" valign="middle" >术前使用例数(个)</th><th align="center" valign="middle" >术后使用例数(个)</th></tr></thead><tr><td align="center" valign="middle" >碳酸钙D3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >22</td></tr><tr><td align="center" valign="middle" >葡萄糖酸钙注射液</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >醋酸钙</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >碳酸澜</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >司维拉姆</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >骨化三醇口服制剂</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >骨化三醇注射液</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >西钠卡塞</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td></tr></tbody></table></table-wrap><p>表4. 术前、术后使用药物情况</p></sec></sec><sec id="s9"><title>5. 讨论</title><p>继发性甲状腺旁腺功能亢进(SHPT)主要发生在慢性肾脏病晚期，由于肾小球滤过率降低，导致钙、磷代谢异常，不断刺激甲状旁腺，引起甲状旁腺增生，导致甲状旁腺激素升高，从而出现骨骼畸形，骨关节痛，皮肤瘙痒，异位钙化，心血管钙化等并发症，早期SHPT可以通过药物得到控制，然而一旦出现甲状旁腺结节样增生，药物治疗效果差，严重影响患者的生存质量。SHPT出现甲状旁腺增生后，多数为同时或先后出现4枚甲状腺旁腺增生 [<xref ref-type="bibr" rid="hanspub.37993-ref7">7</xref>]，本研究发现，大多数病人为4枚甲状旁腺增生，但仍存在3枚、5枚甲状旁腺增生情况，故在术前需要通过彩超及99mTc-MIBI双时相显像进行明确增生甲状旁腺数目，避免手术遗漏，影响消融效果。</p><p>SHPT发病早期是以药物治疗为主的内科治疗，随着疾病的进展，多数患者药物控制不理想，甲状旁腺结节样增生导致PTH不断升高，继而发展成难治性的 SHPT。目前中华医学会制定的CKD-MBD诊治指南、美国改善全球肾脏病预后组织(KDIGO)指南、日本透析学会诊治指南，均推荐甲状旁腺切除术(PTX)作为SHPT药物治疗无效的首选方法 [<xref ref-type="bibr" rid="hanspub.37993-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37993-ref5">5</xref>]。研究表明PTX可明显提高患者生存质量，但由于术中甲状旁腺定位问题，术后复发，以及二次手术等均给患者带来严重的身心和经济负担。</p><p>近年来，随着微创这一概念逐渐深入到外科与内科治疗的各领域，热消融(包括微波、射频、激光消融)技术作为微创的前沿已成功运用到多个领域的治疗，并得到了广泛的一致认可 [<xref ref-type="bibr" rid="hanspub.37993-ref12">12</xref>]。目前尚无公认的介入治疗SHPT适应证，因此目前认为，其治疗指征可与手术治疗相同，甚至对于早期SHPT但存在甲状旁腺结节者，也可以考虑介入治疗 [<xref ref-type="bibr" rid="hanspub.37993-ref13">13</xref>]，因此我们的试验以外科手术指征作为参考。</p><p>本研究发现消融后iPTH值及钙、磷值均明显下降，术后当日iPTH即有明显下降，临床症状明显好转，术后1周内iPTH水平直线下滑，1周后趋于稳定，因此术后效果的评价应在射频消融术后1周。本研究发现，术后症状均明显缓解，其中以骨关节痛、皮肤瘙痒缓解较明显。本研究结果提示，射频消融术后患者钙、磷、甲状旁腺激素等实验室指标明显好转，且具有良好的改善临床症状的效果，因此射频消融术具有明确的治疗效果。</p><p>消融后均会出现低钙血症，但未出现较严重低钙血症抽搐患者，并且经过补钙后血钙能够得到恢复。消融后部分患者出现声音嘶哑等喉返神经损伤表现，但可自行修复，且未出现明显对周围脏器热损伤等并发症。KDOQI指南把甲状旁腺激素( iPTH) &lt; 100 pg/ml作为低转运性骨病的诊断标准之一 [<xref ref-type="bibr" rid="hanspub.37993-ref2">2</xref>]，本研究发现消融后患者血清iPTH明显下降，部分患者iPTH值波动于100 pg/ml，但平均值在指南要求范围之内，射频消融术后低转运骨病发生率低。由此，充分体现了甲状旁腺射频消融术具有并发症少的优点。术后患者所服用的补钙、降磷、治疗甲状旁腺功能亢进等药物明显减少或停用，极大地减轻了病人的痛苦及经济负担。</p><p>因此，射频消融术治疗SHPT在疗效、症状缓解方面有明显作用，且具有并发症少、术后恢复快、微创、痛苦小、操作简便、可反复施行等特点，值得广泛推广。</p><p>然而，由于样本量小，随访时间短，射频消融术治疗SPTH的远期效果如心脑血管终点事件、死亡等还需要进一步临床观察。</p></sec><sec id="s10"><title>文章引用</title><p>王宝福,覃夏川,林昌伟,李波良,谢席胜. 超声引导下经皮穿刺射频消融术治疗尿毒症难治性继发性甲状旁腺功能亢进的临床疗效分析The Clinical Efficacy Analysis of Ultrasound Guided Percutaneous Radiofrequency Ablation in the Treatment of Uremic Refractory Secondary Hyperparathyroidism[J]. 临床医学进展, 2020, 10(10): 2209-2215. https://doi.org/10.12677/ACM.2020.1010334</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37993-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">常欢, 陈航, 李建东, 等. 慢性肾脏病继发甲状旁腺功能亢进的发病机制及治疗进展[J]. 中国血液净化杂志, 2017, 16(4): 273-276.</mixed-citation></ref><ref id="hanspub.37993-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Supplement, 7, 1-59.  
&lt;br&gt;https://doi.org/10.1016/j.kisu.2017.04.001</mixed-citation></ref><ref id="hanspub.37993-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hedgeman, E., Lipworth, L., Lowek, K., et al. (2015) International Burden of Chronic Kidney Disease and Secondary Hyperparathyroidism: A Systematic Review of the Literature and Available Data. International Journal of Nephrology, 2015, Article ID 184321. &lt;br&gt;https://doi.org/10.1155/2015/184321</mixed-citation></ref><ref id="hanspub.37993-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">罗丽花, 查爱云, 管保章, 等. 超声引导下经皮热消融治疗继发性甲状旁腺功能亢进的研究进展[J]. 中国血液净化杂志, 2016, 8(15): 421-423.</mixed-citation></ref><ref id="hanspub.37993-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">中国慢性肾脏病矿物质和骨异常专家组. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 54.</mixed-citation></ref><ref id="hanspub.37993-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">程晨, 张丽娜, 王宁宁, 等. 超声引导下微创治疗严重继发性甲状旁腺功能亢进症[J]. 中华骨质疏松和骨矿盐疾病杂志, 2016, 9(4): 428-430.</mixed-citation></ref><ref id="hanspub.37993-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">章建全, 黄宝砖, 梅长林. 继发性甲状旁腺功能亢进的超声影像[J]. 第二军医大学学报, 2002(23): 1252-1254.</mixed-citation></ref><ref id="hanspub.37993-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J. and Wang, J.D. (2014) Radioguided Parathyroidectomy in Patients with Secondary Hyperparathyroidism due to Chronic Renal Failure. Nuclear Medicine Communications, 35, 391-397.  
&lt;br&gt;https://doi.org/10.1097/MNM.0000000000000062</mixed-citation></ref><ref id="hanspub.37993-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sadideen, H.M., Taylor, J.D. and Goldsmith, D.J. (2012) Total Parathyroidectomy without Autotransplantation after Renal Transplantation for Tertiary Hyperparathyroidism: Long-Term Follow-Up. International Urology and Nephrology, 44, 275-281. &lt;br&gt;https://doi.org/10.1007/s11255-011-0069-9</mixed-citation></ref><ref id="hanspub.37993-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Douthat, W.G., Cardozo, G., Garay, G., et al. (2011) Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy. International Journal of Nephrology, 2011, Article ID 246734. &lt;br&gt;https://doi.org/10.4061/2011/246734</mixed-citation></ref><ref id="hanspub.37993-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Schneider, R., Slater, E.P. and Karakas, E. (2012) Initial Parathyroid Surgery in 606 Patients with Renal Hyperparathyroidism. World Journal of Surgery, 36, 318-326. &lt;br&gt;https://doi.org/10.1007/s00268-011-1392-0</mixed-citation></ref><ref id="hanspub.37993-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识[J]. 肿瘤, 2011, 31(5): 385-388.</mixed-citation></ref><ref id="hanspub.37993-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">刁宗礼, 王丽妍, 刘莎, 等. 继发性甲状旁腺功能亢进的介入和手术治疗进展[J]. 大连医科大学学报, 2016, 38(3): 298-230.</mixed-citation></ref></ref-list></back></article>